Safety and Efficacy Evaluation of Traditional Chinese Medicine (Qingre-Lishi-Yishen Formula) Based on Treatment of Regular Glucocorticoid Combined with Cyclophosphamide Pulse in Children Suffered from Moderately Severe Henoch-Schonlein Purpura Nephritis with Nephrotic Proteinuria
- PMID: 32047523
- PMCID: PMC7007748
- DOI: 10.1155/2020/3920735
Safety and Efficacy Evaluation of Traditional Chinese Medicine (Qingre-Lishi-Yishen Formula) Based on Treatment of Regular Glucocorticoid Combined with Cyclophosphamide Pulse in Children Suffered from Moderately Severe Henoch-Schonlein Purpura Nephritis with Nephrotic Proteinuria
Abstract
Objective: At present, the most appropriate management of Henoch-Schonlein purpura nephritis (HSPN) with nephrotic-range proteinuria still remains controversial; thus, the purpose of this study is to evaluate safety and efficacy of traditional Chinese medicine (TCM), Qingre-Lishi-Yishen Formula (QLYF), integrated with regular oral glucocorticoid and cyclophosphamide intravenous pulse therapeutic regimen in children suffered from moderately severe HSPN with nephrotic proteinuria.
Methods: From 1 January 2012, to 1 January 2016, totally 150 hospitalized children suffered from HSPN with nephrotic proteinuria were included. All were treated with glucocorticoid and cyclophosphamide, and 100 of them were treated with integrative traditional Chinese decoction QLYF. Patients were followed up for 2 years. Rate of adverse event occurrence, short-term clinical effects, long-term clinical effects, and TCM therapeutic evaluation were all compared.
Results: Total adverse event rate was lower in the QLYF group (χ 2 = 5.357, p = 0.022); rates of respiratory infection, urinary infection, poor appetite, hepatotoxity, cardiotoxicity, and neutropenia were all decreased in patients who received QLYF (p = 0.022); rates of respiratory infection, urinary infection, poor appetite, hepatotoxity, cardiotoxicity, and neutropenia were all decreased in patients who received QLYF (p = 0.022); rates of respiratory infection, urinary infection, poor appetite, hepatotoxity, cardiotoxicity, and neutropenia were all decreased in patients who received QLYF (p = 0.022); rates of respiratory infection, urinary infection, poor appetite, hepatotoxity, cardiotoxicity, and neutropenia were all decreased in patients who received QLYF (p = 0.022); rates of respiratory infection, urinary infection, poor appetite, hepatotoxity, cardiotoxicity, and neutropenia were all decreased in patients who received QLYF (p = 0.022); rates of respiratory infection, urinary infection, poor appetite, hepatotoxity, cardiotoxicity, and neutropenia were all decreased in patients who received QLYF (.
Conclusion: Compared with merely using regular oral glucocorticoid plus cyclophosphamide pulse therapeutic regimen, the therapeutic regimen that integrates QLYF with the abovementioned western medicine might be a safe means to decrease the occurrence rate of adverse events and improve short-term and long-term clinical effects in children who suffered from moderately severe HSPN with nephrotic proteinuria.
Copyright © 2020 Lirong Fan et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Figures


Similar articles
-
Traditional Chinese medicine versus regular therapy in Henoch-Schönlein purpura nephritis in children: study protocol for a randomized controlled trial.Trials. 2019 Aug 29;20(1):538. doi: 10.1186/s13063-019-3484-3. Trials. 2019. PMID: 31464626 Free PMC article.
-
Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.Med Sci Monit. 2017 May 18;23:2333-2339. doi: 10.12659/msm.904206. Med Sci Monit. 2017. PMID: 28515415 Free PMC article.
-
Correlation between endocapillary proliferative and nephrotic-range proteinuria in children with Henoch-Schönlein purpura nephritis.Pediatr Nephrol. 2019 Apr;34(4):663-670. doi: 10.1007/s00467-018-4134-9. Epub 2018 Nov 10. Pediatr Nephrol. 2019. PMID: 30415419
-
Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management.World J Pediatr. 2015 Feb;11(1):29-34. doi: 10.1007/s12519-014-0534-5. Epub 2014 Dec 29. World J Pediatr. 2015. PMID: 25557596 Review.
-
Adjuvant treatments for Henoch-Schönlein purpura nephritis in children: A systematic review.Curr Ther Res Clin Exp. 2009 Jun;70(3):254-65. doi: 10.1016/j.curtheres.2009.05.003. Curr Ther Res Clin Exp. 2009. PMID: 24683235 Free PMC article. Review.
Cited by
-
Study on the clinical mechanism of Tong-Xie-An-Chang Decoction in the treatment of diarrheal irritable bowel syndrome based on single-cell sequencing technology.Medicine (Baltimore). 2020 Dec 24;99(52):e23868. doi: 10.1097/MD.0000000000023868. Medicine (Baltimore). 2020. PMID: 33350782 Free PMC article. Clinical Trial.
-
Efficacy and safety of Chinese herbal medicine in treating postcholecystectomy diarrhea: A systematic review and meta-analysis.Medicine (Baltimore). 2024 May 3;103(18):e38046. doi: 10.1097/MD.0000000000038046. Medicine (Baltimore). 2024. PMID: 38701312 Free PMC article.
-
[Therapeutic effect of mycophenolate mofetil or cyclophosphamide in children with Henoch-Schönlein purpura nephritis of different age groups].Zhongguo Dang Dai Er Ke Za Zhi. 2023 Nov 15;25(11):1113-1117. doi: 10.7499/j.issn.1008-8830.2306085. Zhongguo Dang Dai Er Ke Za Zhi. 2023. PMID: 37990454 Free PMC article. Chinese.
-
Influence of transitional nursing on the compliance behavior and disease knowledge of children with purpura nephritis.World J Clin Cases. 2020 Nov 6;8(21):5213-5220. doi: 10.12998/wjcc.v8.i21.5213. World J Clin Cases. 2020. PMID: 33269257 Free PMC article.
-
Proanthocyanidins: A novel approach to Henoch‑Schonlein purpura through balancing immunity and arresting oxidative stress via TLR4/MyD88/NF‑κB signaling pathway (Review).Exp Ther Med. 2023 May 9;25(6):300. doi: 10.3892/etm.2023.11999. eCollection 2023 Jun. Exp Ther Med. 2023. PMID: 37229322 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources